STI NG resides on the ER and is activated by cGAMP, a cyclic dinucleotide second messenger that is produced by cGAMP synthase (cGAS) upon detection of cytosolic host or microbial DNA (Stetson, 2012; Schoggins et al., 2014; West et al., 2015; Li et al., 2016) . Binding of cGAMP to STI NG triggers a conformational change in the STI NG C terminus (Ouyang et al., 2012) and subsequent ER-to-vesicle trafficking (Dobbs et al., 2015) , which activates downstream effectors including TANK-binding kinase 1 (TBK1; Tanaka and Chen, 2012) and IκB kinase (Ishikawa and Barber, 2008) . TBK1 phosphorylates IRF3, which leads to IRF3 translocation into the nucleus and transcriptional activation of IFN-β and ISGs (Li et al., 2016; Wang et al., 2016) . Activation of the type I IFN response via IRF3 is thought to be the driving force behind SAVI disease pathogenesis (Liu et al., 2014) , although this hypothesis was not previously tested experimentally in an animal model of the disease. Interestingly, one recent study provided evidence that abnormalities in T cell proliferation in human patients with SAVI occur independently of any interaction with TBK1 and IRF3 (Cerboni et al., 2017) . Thus, there is a need for models of SAVI that will allow in vivo testing of previously hypothesized mechanisms of disease pathogenesis, beyond cell culture studies of IRF3 activation. Here, we describe the generation of STI NG N153S knock-in mice as a model of SAVI. Like SAVI patients, the mice developed T cell cytopenia, myeloid cell expansion, and spontaneous pulmonary inflammation, which occurred independently of IRF3 in mice.
reSultS

StI nG n153S mice develop spontaneous lung and skin disease, causing premature death
The original description of SAVI found that four of six patients had the STI NG N154S mutation (Liu et al., 2014;  N153S in mouse STI NG), a mutation that we previously confirmed to cause up-regulation of type I IFN in 293T cell assays (Dobbs et al., 2015) . Thus, we chose to introduce the STI NG N153S mutation in mice to produce a model of SAVI. Using CRI SPR/Cas9, we generated heterozygous STI NG N153S mice by introducing a DNA oligonucleotide donor containing a two-nucleotide missense mutation into exon 5 of TMEM173 (STI NG), which resulted in replacement of asparagine 153 with serine (STI NG N153S; Fig. 1 A) . Homozygous knock-in mice did not survive gestation, whereas adult STI NG N153S heterozygous animals (STI NG N153S mice) developed spontaneous disease characterized by splenomegaly ( Fig. 1 B) , pleural effusions ( Fig. 1 C) , and ulcerative skin lesions of the extremities of five mice and on the head of one 9-mo-old STI NG N153S animal ( Fig. 1 D) . Severe respiratory distress occurred frequently, required euthanasia, and was sometimes observed during late pregnancy in STI NG N153S dams that were unable to survive labor (Fig. 1 E) . Histopathological evaluation of the lung revealed chronic perivascular inflammation with heterogeneous immune cell infiltration ( Fig. 2 A, black arrows) and organized thrombosis in pulmonary blood vessels ( Fig. 2 A, red arrows) . Higher-magnification images (Fig. 2 B) and flow cytometric analysis of immune cells in the lungs of STI NG N153S mice revealed substantially increased numbers of immune cells (two-to fourfold, P < 0.05), predominantly consisting of CD19 + B cells and CD11b + myeloid cells, with smaller numbers of CD4 + and CD8 + T cells ( Fig. S1 ). Because SAVI patients frequently develop interstitial lung disease, we performed a histological assessment for pulmonary fibrosis by Gomori trichrome staining of STI NG N153S lungs, but we found no evidence of pulmonary fibrosis, even in animals that were evaluated at necropsy after spontaneous death caused by respiratory distress ( Fig. 2 C) . Histopathological assessment of skin lesions revealed mixed immune cell infiltration, ulceration, and scarring ( Fig. 2 D) . Some features of disease are shared in SAVI and systemic lupus erythematosus (Balada et al., 2016) , but unlike many patients with systemic lupus, SAVI patients do not develop glomerulonephritis. Consistent with SAVI in humans, we found no evidence of inflamed or abnormal glomeruli in STI NG N153S mice (Fig. 2 E) . However, histopathological examination of the spleen consistently demonstrated abnormal architecture ( Fig. 2 F) , suggesting that the STI NG N153S mutation may trigger immune cell dysregulation in secondary lymphoid organs.
Because some SAVI patients develop autoantibodies (Liu et al., 2014) , we quantitated levels of total IgM and IgG antibodies and performed autoantigen array analysis of serum from STI NG N153S mice and WT littermate control animals. Three of five STI NG N153S mice produced higher levels of IgM but not IgG autoantibodies compared with WT littermates (Fig. 3 ). However, all five of the STI NG N153S mice had severe lung disease, including animals without detectable autoantibodies, suggesting that autoantibodies are not required for disease pathogenesis in mice. A multiplexed cytokine assay performed on the serum of 4-6-mo-old STI NG N153S mice and WT littermate controls revealed el-evated levels of multiple cytokines and chemokines including TNF, IL-17A, IL-13, G-CSF, MIP-1α, MIP-1β, MCP-1, and IL-10 (2-23-fold increase, P < 0.05; Fig. 4 ). Thus, STI NG N153S mice develop hypercytokinemia and spontaneous inflammation of the lung and skin. the StI nG n153S mutation causes myeloid cell expansion and cell-intrinsic t cell cytopenia SAVI patients were previously reported to have T cell cytopenia and impaired myeloid cell differentiation (Liu et al., 2014) . To begin to characterize immune cells in STI NG N153S mice, we used cytometry by time-of-flight (CyTOF) to assess immune cell populations in the spleen (Fig. 5 ). Although we detected no difference in numbers of splenic CD45 + and CD19 + cells in STI NG N153S mice, there was a deficiency in T cells (22 × 10 6 CD3 + cells in WT vs. 2.9 × 10 6 in STI NG N153S; P < 0.005), which was more severe, and consistently observed, for CD8 + T cells than for CD4 + T cells ( Fig. 5 , A-C and F-H). Additionally, we observed marked expansion of Ly6G + myeloid cells (0.6 × 10 6 in WT vs. 9.5 × 10 6 in STI NG N153S; P < 0.005; Fig. 5 , A-C and I) and immature myeloid cells (CD11b + cKit + MHC II − ; Fig. 5 A) . Also, in T and NK cells, activation markers including CD44 were up-regulated (Fig. 5, J and K) , which may occur as a direct result of cell-intrinsic STI NG signaling or may reflect an indirect consequence of chronic hypercytokinemia.
To test whether T cell cytopenia may result from cell-intrinsic effects of the STI NG N153S mutation, we generated mixed bone marrow chimeras by comparing WT Thy1.1 + versus either WT littermate control or STI NG N153S marrow transplanted into CD45.1 recipients ( Fig. 6 A) . In the competition between the Thy1.1 + and STI NG N153S donors, CD4 + and CD8 + T cells were predominantly generated from WT Thy1.1 + bone marrow, revealing that the STI NG N153S T cell deficiency is intrinsic to the hematopoietic compartment (Fig. 6 , B and C). To further evaluate the cause of splenic T cell deficiency, we performed CyTOF analysis of thymocytes ( Fig. 7) and found a decrease in total numbers of thymocytes (2.7-fold in STI NG N153S compared with WT, P < 0.005), a large increase in the number and percent of thymic B cells (0.13% in WT vs. 2.5% in STI NG N153S, P < 0.005), and a lower fraction of double-negative T cells (1.8% in WT vs. 1.2% in STI NG N153S, P < 0.005; Fig. 7 ). Although diminished in total number, the percentages of individual thymocyte subsets did not suggest a block at any specific stage in T cell development. Evaluation of mixed bone marrow chimeric mice confirmed diminished STI NG N153S T cell numbers at all stages of development, including at the DN1 stage, consistent with what was observed in mixed chimeric mice ( Fig. 7 N) . These results suggest that the STI NG N153S mutation exerts hematopoietic cell-intrinsic deleterious effects on the early stages of thymocyte development. This result also is consistent with prior in vitro studies demonstrating that a different SAVI-associated mutation (STI NG V155M) caused cell-intrinsic effects in human T cells (Cerboni et al., 2017) , although our in vivo findings sug- gest that T cell cytopenia results mostly from cell-intrinsic effects on early T cell precursors.
Activation of StAt and mtorc1 signaling in StI nG n153S splenocytes
To further investigate the effects of STI NG N153S on cell signaling, we used CyTOF to assess phosphorylation status of TBK1, STAT1, STAT3, STAT5, SHP2, 4E-BP1, S6, and the presence of Ki67, a marker of cellular proliferation. In STI NG N153S splenocytes, we observed a pronounced activation of the mTORC1 pathway (phospho-S6 and phospho-4E-BP1) in immune cell subsets known to express STI NG (monocytes, T cells, NK cells, and cKit + immature myeloid cells; Liu et al., 2014; Kobayashi et al., 2015) as well as increased activation of STAT3 and STAT5 in monocytes and NK cells, respectively (Fig. 8, A and B) . These data suggest that the STI NG N153S mutation results in activation of mTORC1, STAT3, and STAT5 signaling in specific immune cell subsets that may occur as a result of either cell-intrinsic or -extrinsic effects of the mutation.
Because SAVI patient PBMCs exhibit a type I IFN gene expression signature (Liu et al., 2014) , we examined whether STI NG N153S mice also up-regulate expression of ISGs. Using RNA-sequencing, and confirmed by quantitative RT-PCR (qRT-PCR), we detected only an approximately twofold up-regulation of ISGs in MEFs and splenocytes compared with WT littermate controls ( Fig. 9, A and B) , suggesting only mild up-regulation of type I IFN signaling. This ISG signature is much weaker in comparison to Trex1 −/− mice, which exhibit constitutive STI NG activation and an interferonopathy with clinically distinct manifestations of disease (Morita et al., 2004) , and in which the majority of ISGs within the same panel were markedly elevated (17-fold compared with WT littermate controls; Fig. 9 , A and B). Because Trex1 −/− cells accumulate self-DNA that constitutively activates STI NG through the cGAS-STI NG-TBK1-IRF3 pathway (Hasan et al., 2013) , our results collectively suggest that STI NG N153S does not cause potent activation of type I IFN signaling in vivo in mice. Next, we decided to correlate our findings with human SAVI patient samples and found that only one of two SAVI patient fibroblasts with the STI NG N154S mutation exhibited significant up-regulation of ISG expression ( Fig. 9 , C and D). Similarly, we did not detect enhanced cGAMP-mediated activation of STI NG in patient cells compared with healthy controls or in STI NG N153S MEFs compared with WT littermate control MEFs (Fig. S2 , A-F), although we observed up-regulation of ISGs in 293T cells that overexpress mouse STI NG N153S in this study (Fig. S2 G) and also in our prior study comparing human STI NG N154S and mouse STI NG N153S in parallel (Dobbs et al., 2015) . These findings suggest that the STI NG mutations may exhibit differential effects in cell lines and in primary cells, or that overexpression produces a more pronounced effect on expression of ISGs.
SAVI has been postulated to result from STI NGmediated activation of IRF3, which potently up-regulates expression of ISGs, so we initially hypothesized that genetic deletion of IRF3 would rescue the mice from disease. To test this hypothesis, we generated Irf3 −/− STI NG N153S mice. Unexpectedly, we observed a similar degree of perivascular immune cell infiltration in Irf3 −/− STI NG N153S mice compared with STI NG N153S control animals ( Fig. 9 , E and F). Conversely, Irf3 −/− STI NG N153S MEFs exhibited reduced IFIT1 and ISG15 expression compared with STI NG N153S MEFs ( Fig. 9 G) , confirming that IRF3 is required for STI NG N153S-dependent up-regulation of IFIT1 and ISG15. IRF7 is up-regulated in a positive feedback loop downstream of IRF3 and IFN-β (Marié et al., 1998; Sato et al., 1998 ), but we did not detect any up-regulation of IRF7 in vivo or in vitro ( Fig. 9 , A-D).
To determine whether IRF3 is required for STI NG N153S-mediated myeloid cell expansion and T cell cytopenia, we assessed WT, STI NG N153S, Irf3 −/− , and Irf3 −/− STI NG N153S splenocytes by flow cytometry. We observed similarly increased numbers of Ly6G + and Ly6C + myeloid cell populations in Irf3 −/− STI NG N153S mice and STI NG N153S control animals ( Fig. 9 , H-J; P > 0.7). Additionally, the percent and absolute number of CD8 + T cells were similarly reduced in splenocytes from Irf3 −/− STI NG N153S and STI NG N153S mice (Fig. 9 , K and L) compared with their respective controls. Thus, lung disease, myeloid cell expansion, and CD8 + T cell cytopenia occur independently of IRF3 signaling in this STI NG N153S mouse model of SAVI.
dIScuSSIon
Our study demonstrates that a SAVI-associated STI NG mutation causes spontaneous inflammatory lung and skin disease in mice. However, certain features of the disease in mice were distinct from clinical features of SAVI in humans. For example, STI NG N153S mice did not develop pulmonary fibrosis, and we did not observe a significant type I IFN gene expression signature in mice, which has been reported in humans with SAVI. However, species-specific effects of a disease-causing mutation are not entirely unexpected. For example, humans lacking functional TREX1, which leads to type I IFN production caused by constitutive STI NG signaling, develop spontaneous brain inflammation (Crow et al., 2006) , whereas mice lacking Trex1 develop an interferonopathy with myocarditis (Morita et al., 2004) . In contrast to the differential effects of Trex1 mutations in humans and mice, STI NG N153S mice and SAVI patients have some interesting cross-species similarities, including organ-specific inflammation (e.g., skin and lung disease) as well as T cell cytopenia.
Up-regulation of ISGs occurs in PBMCs of SAVI patients (Liu et al., 2014; Picard et al., 2016) , but whether type I IFN plays a causal role in the human disease remains to be determined. Importantly, some of the clinical manifestations of SAVI are distinct from other interferonopathies such as Aicardi-Goutières syndrome, a disease in which the STI NG pathway is chronically activated because of loss of TREX1 function (Crow and Manel, 2015) . One view is that SAVI pathogenesis is mediated by IRF3-induced activation of the type I IFN response (Liu et al., 2014; Kim et al., 2016; Melki et al., 2017) , as occurs in other interferonopathies (Crow and Manel, 2015; Kim et al., 2016) , but this had not previously been tested experimentally in an animal model with a human disease-causing STI NG mutation. We observed only mild effects on ISG expression in STI NG N153S MEFs, and these effects were abolished in the absence of IRF3 ( Fig. 9 G) , demonstrating that there was indeed some mild IRF3-dependent up-regulation of certain ISGs in MEFs. Additionally, we observed mild up-regulation of ISGs in patient fibroblast cell lines bearing the STI NG N154S mutation. Our results demonstrate that the STI NG N153S mutation causes inflammatory lung and skin disease in mice without substantive up-regulation of ISGs in primary cells, without up-regulation of IRF7 in vivo or in vitro, and without IRF3, a major downstream effector thought to promote disease in patients with SAVI. Nevertheless, additional studies in STI NG N153S mice lacking the type I IFN receptor are still required to completely exclude any contribution of type I IFN in this mouse model of SAVI. Given that IRF3 does not play a role in the disease in mice, it seems plausible that STI NG mutations in humans also cause disease via other mechanisms and that up-regulation of type I IFN in patient PBMCs might be an epiphenomenon. Alternatively, mechanisms of disease pathogenesis may be entirely distinct in humans with SAVI and the STI NG N153S mice, with type I IFN playing a more important role in the human disease.
In patients with systemic sclerosis and interstitial lung disease, there is an association between type I IFN and pulmonary fibrosis, suggesting a possible role for type I IFN in fibrosing lung disease (Eloranta et al., 2010) . Based on association, pulmonary fibrosis in SAVI patients also may be influenced by type I IFN (Picard et al., 2016) . We found that the STI NG N153S knock-in mice universally developed chronic lung inflammation by age 3-4 mo, but without evidence of fibrosis even in mice that were examined after death from respiratory distress. However, mice older than 6 mo were not assessed. Chronic inflammation may eventually cause fibrosis in older animals that survive longer. Alternatively, the relative absence of a type I IFN gene expression signature in STI NG N153S mice may be one reason the animals failed to develop fibrosing lung disease.
STI NG exerts multiple effects on the pathogenesis of autoimmune disease. Aside from its capacity to up-regulate ISGs, the TREX1-cGAS-STI NG pathway modulates cellular senescence (Yang et al., 2017) , adaptive immunity (Fu et al., 2015; Cerboni et al., 2017) , and production of proinflamma-tory cytokines (Abe and Barber, 2014) . Paradoxically, STI NG also limits autoantibody generation and type I IFN production as well as nephritis in lupus-prone mice (Sharma et al., 2015) . Furthermore, STI NG deficiency unexpectedly led to hyperresponsiveness of macrophages to TLR7 and TLR9 ligands (Sharma et al., 2015) . Thus, in addition to its effects on type I IFN signaling, the STI NG N153S mutation is likely to influence multiple cellular and immunological pathways in a variety of ways that also could contribute to disease.
A prior study found that STI NG regulates T cell proliferation in cell culture independently of IRF3 (Cerboni et al., 2017) . Consistent with these previous in vitro findings that used SAVI patient cells with the V155M mutation, we demonstrated that the STI NG N153S mutation affects T cells in mice in an IRF3-independent manner, and that this was caused by hematopoietic cell-intrinsic effects. In addition to altered proliferation of T cells, our mixed bone marrow chi- mera studies revealed that STI NG N153S impacts T cells at the early stages of thymocyte development. Similar to the effects of STI NG N153S on T cells, myeloid cell expansion in the STI NG N153S mice also occurred independently of IRF3. Because the STI NG N153S mice develop immune cell abnormalities resembling those observed in SAVI patients, future therapeutic studies will determine whether WT bone marrow transplantation into STI NG N153S recipients may protect animals from disease, which may have implications for clinical practice.
In summary, our STI NG N153S knock-in mouse model demonstrates a role for a human disease-causing mutation in immune cell homeostasis and inflammatory lung and skin disease in mice. This mouse model will serve as an important tool to define mechanisms of STI NG-induced autoinflammatory disease, including type I IFNindependent effects, in the context of a human diseasecausing mutation.
MAterIAlS And MetHodS design
The goal of our study was to define the disease phenotype of mice heterozygous for the STI NG N153S mutation. Power analysis was conducted for institutional animal care and use committee-approved in vivo studies to determine the number of animals needed per experimental group. A minimum of two independent in vivo experiments were conducted to replicate findings. No randomization of animals was used for experiments, but WT littermate control animals were used in all studies of STI NG N153S mice. No outliers were excluded from analyses. There was no blinding with regard to data analyses with the exception of histological analysis, which was carried out in a blinded fashion. The number of technical and biological replicates for each experiment is listed in the figure legends.
Study approvals
Patient fibroblasts were provided by R. Goldbach-Mansky (NIA ID, NIH, Bethesda, MD), were de-identified, and were studied under UT Southwestern Medical Center institutional review board approval for de-identified human samples. Animal protocols were approved by the Institutional Animal Care and Use Committees at the Washington University School of Medicine (assurance no. A-3381-01) and UT Southwestern Medical Center (assurance no. APN2011-0081).
Generation of StI nG n153S knock-in mice
A single guide RNA (sgRNA; 5′-GTT AAA TGT TGC CCA CGG GCT GG-3′) was designed based on specificity and proximity to the targeted Tmem173 (STI NG) mutation site. Efficiency of genomic DNA cutting was tested in an in vitro cell line assay as previously described (Parikh et al., 2015) . T7 templates for gRNA and WT Cas9 (px330) were prepared by PCR amplification and purified by Qiaquick PCR purification spin columns (Qiagen). RNA synthesis was then performed according to the manufacturer's protocol using the Megashortscript kit (Thermo Fisher Scientific) and mMES SAGE mMAC HINE T7 Ultra kit (Thermo Fisher Scientific), for sgRNA and Cas9 mRNA, respectively. RNA was purified using MEGAclear RNA purification kit (Life Technologies; sgRNA) or by lithium chloride precipitation (Cas9 mRNA) and diluted in nuclease-free injection buffer. A single-stranded oligonucleotide donor (ssODN) encoding the amino acid substitution (N153S) with 99-nucleotide homology arms was synthesized by IDT (Ultramer oligo): 5′-gctttggacatcccccttgaaagtccctcag-gcccttctgctgtcttcagAGC TTG ACT CCA GC-GGA AGT CTC TGC AGT CTG TGA AGA AAA GAA GTTAtcTGT TGC CCA CGG GCT GGC CTG GTC ATA CTA CAT TGG GTA CTT GCG GTT GAT CTT ACC AGgtagggcacctctggatgttgatgtgtggacaacaaaacac-3′ (exonic sequence in uppercase, flanking intronic sequence in lowercase, and mutant nucleotides in underlined lowercase). Female C57BL/6N mice, 4 wk of age, were superovulated and mated with C57BL/6N males. Single-cell embryos (embryonic day 0.5 [E0.5]) were isolated and injected with a combination of either 50 ng/μl Cas9, 25 ng/ μl gRNA, and 100 ng/μl ssODN or a combination of 25 ng/ μl Cas9, 13 ng/μl gRNA, and 100 ng/μl ssODN in DNase/ RNase-free microinjection buffer (1 mM Tris and 0.25 mM EDTA, pH 7.4). Over the course of 6 d of microinjection, ∼80-100 modified embryos per day were transferred into E0.5 pseudo-pregnant ICR/CD1 female recipient mice. Two in-dependent founder mice were backcrossed to WT animals for five generations, and WT littermate controls were used for all experiments. Experiments were performed on mice between 12 and 24 wk of age, including equal numbers of mice of both sexes, with matched littermate control animals. Sample sizes were chosen according to our previously published studies. Mice were randomly allocated for all experiments.
Mice
Mice were housed in pathogen-free mouse facilities at the Washington University School of Medicine and UT Southwestern Medical Center and given standard diet and water ad libitum. ICR/CD1 mice were provided by the Hope Transgenic Mouse Core at Washington University in St. Louis. Sting −/− mice were gifts from G. Barber (University of Miami, Miami, FL). The congenic backcrossed Irf3 −/− mice (Sato et al., 2000) were gifts of T. Taniguchi (Tokyo, Japan) and provided by colleagues in the United States (I. Rifkin, Boston, MA; K. Fitzgerald, Worcester, MA).
Generation of mixed bone marrow chimeras
Femurs, tibias, and pelvises were dissected from STI NG N153S, WT littermate controls, and Thy1.1 mice. Bone marrow was flushed from bones, and red blood cells were lysed with ACK lysis buffer. Debris was removed by passing cells through a 70-µM strainer and counted via hemocytometer. WT or STI NG N153S bone marrow was mixed with Thy1.1 bone marrow at a 1:1 ratio, and a total of 10 × 10 6 cells were transplanted into CD45.1 hosts via retroorbital i.v. injection. Hosts received two doses of whole-body irradiation (500 rads, total 1,000 rads) 5 h apart, 24 h before transplantation. Chimeras were bled 6 wk after transplantation for FACS analysis of circulating immune cells. Three animals per group were euthanized ∼10 wk after transplantation for analysis of thymocytes.
Antibodies and other reagents
Antibodies used for flow cytometry include the following: FITC-anti-CD19 (rat IgG2a; 1:200, #115506; BioLegend), PE-anti-CD45.1 (mouse [A.SW] IgG2a; 1:100, #110707; BioLegend), PE/Cy7-anti-Thy1.1 (mouse IgG1; 1:100, #202518; BioLegend), BV421-anti-CD4 (rat IgG2b; 1:150, #100438; BioLegend), APC-anti-CD45.2 (mouse [SJL] IgG2a; 1:100, #109813; BioLegend), V500-anti-CD3e (Syrian hamster IgG2; 1:50, #560771; BD Biosciences), FITCanti-CD25 (rat IgG2b; 1:100, #101907; BioLegend), PerCP/ Cy5.5-anti-CD19 (rat IgG2a; 1:100, #152405, BioLegend), PerCP/Cy5.5-anti-NK1.1 (mouse IgG2a; 1:100, #108727; BioLegend), PerCP/Cy5.5-anti-CD8b (rat IgG2b; 1:100, #126609; BioLegend), BV605-anti-CD44 (rat IgG2b; 1:100, #103047; BioLegend), FITC-anti-CD8a (rat IgG2a; 1:100, STI NG N153S mice. Data represent the mean of two independent experiments with n = 4 or 5 mice per genotype. (K and L) Percentage (K) and total number (L) of CD8 + splenocytes from WT, STI NG N153S, Irf3 −/− , and Irf3 −/− STI NG N153S mice. Data were pooled from two independent experiments with n = 4 or 5 mice per genotype. ns, not significant; *, P < 0.05; **, P < 0.005 by Mann-Whitney test. #100705; BioLegend), BV510-anti-CD11b (rat IgG2b; 1:100, #101245; BioLegend), BV421-anti-Ly6C (RçAT IgM; 1:100, #562727; BD Biosciences), and PerCP/Cy5.5-anti-Ly6G (rat IgG2a; 1:100, #127615; BioLegend). For mass cytometry experiments, metal-tagged antibodies were obtained from Fluidigm or conjugated using the Maxpar X8 Antibody Labeling kit according to the manufacturer's instructions (Fluidigm) . Clone and tag information can be found in Table S1 .
Genotyping
Toe clips were digested with proteinase K, and DNA was isolated with the Qiagen kit per manufacturer's protocol. Two separate PCR reactions were performed for genotyping: a WT allele PCR and a STI NG N153S mutant allele PCR. WT primer (5′-GTC TGT GAA GAA AAG AAG TTA AA-3′) or STI NG N153S forward primer (5′-GTC TGT GAA GAA AAG AAG TTA AC-3′) and reverse primer (5′-GTG ATT TTA TGT ACC CTG GG-3′) recognizing sequences in exon 5 of Tmem173 (STI NG) were added to PCR SuperMix (Invitrogen) at a final concentration of 0.4 µM. PCR was performed with an initial denaturation (94°C, 2 min), followed by 34 cycles of denaturation (94°C, 30 s), annealing (47°C, 45 s), and extension (72°C, 1 min). Mice positive for the STI NG N153S mutation were identified by the appearance of a 258-bp band by agarose gel electrophoresis.
Primary cell isolation and culture
Primary WT littermate, heterozygous STI NG N153S, Irf3 −/− , Irf3 −/− heterozygous STI NG N153S, and Sting −/− MEFs (Ishikawa and Barber, 2008 ; gift from G. Barber) were generated from embryos on E13.5. MEFs were transfected with SV2 plasmid, encoding the large T antigen of SV40 polyomavirus. Cells were passaged ∼10 times and used for subsequent experiments. In some experiments, primary MEFs were used to confirm phenotypes observed in transformed MEFs. Cell lines were genotyped to confirm their identity. Human fibroblasts were generated from SAVI patients and healthy controls (Liu et al., 2014;  gift to the Yan laboratory from R. Goldbach-Mansky). All cells were cultured at 37°C with 5% CO 2 in DMEM supplemented with 10% FBS and 2 mM l-glutamine, 1× nonessential amino acid solution, 1 mM sodium pyruvate, 10 mM Hepes, 100 U/ml penicillin, and 100 mg/ml streptomycin. cytokine assay Mouse serum was collected by terminal exsanguination of anesthetized mice and stored at −20°C before measurement of cytokine and chemokine levels on the Luminex platform using the Bio-Plex Pro Mouse Cytokine Group I Panel 23-Plex Assay kit (Bio-Rad). The BioPlex Pro Assay was performed according to the manufacturer's protocol. Cytokines and chemokines tested include IL-1α, IL-1β, IL-2, IL-3 IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-17, eotaxin, G-CSF, GM-CSF, IFN-γ, Iα, MIP-1β, RAN TES (CCL5), and TNF.
Autoantigen arrays
Autoantigen arrays were performed on serum samples by the University of Texas Southwestern Medical Center Microarray Core as previously described (Li et al., 2005) .
Stimulation of cell lines with cGAS-StI nG ligands
Transfections of 2′3′-cGAMP (Invivogen), htDNA (Sigma-Aldrich), and poly I:C (Sigma-Aldrich) were performed using Lipofectamine 2000 (Thermo Fisher Scientific) as previously described (Dobbs et al., 2015) . After 6 h of treatment, RNA was isolated using Trizol (Sigma-Aldrich), and ISGs and IFN-β were measured via qRT-PCR.
qrt-Pcr
Total RNA was isolated by RNeasy kit (Qiagen) per manufacturer's protocol. RNA was quantified and quality confirmed using a NanoDrop ND-1000 spectrophotometer. cDNA was synthesized with iScript cDNA synthesis kit (Bio-Rad). iTaq Universal SYBR Green Supermix (Bio-Rad) and an ABI-7500 Fast Real-Time PCR system (Applied Biosystems) were used for qRT-PCR. Alternatively, in some experiments, TaqMan RNA-to-Ct 1-Step kit (Applied Biosystems) was used to measure mRNA expression. Ct values for all target genes were normalized to Ct values of the housekeeping gene GAP DH. Data are reported as ΔCt (Ct target -Ct GAP DH ). cytoF Spleen and thymus tissues were isolated from WT and STI NG N153S mice and mashed through 70-µm Nylon cell strainers, washed twice with culture media, and treated with RBC lysis buffer. Cells were then washed with CyFACS (0.1% BSA, 2 mM EDTA, and 0.02% NaN 2 in PBS; Rockland) followed by CyPBS. For viability staining, cells were incubated with 2.5 µM cisplatin for 1 min at room temperature, washed twice in CyFACS, and fixed in 1.5% PFA (final concentration) for 10 min at room temperature. After two washes, 3 × 10 6 cells per sample were incubated for 10 min with Fc block, after which a cocktail of 17 surface markers (Table S1 ) was added and incubated with the cells for 1 h on ice. Cells were washed in Cy-FACS and permeabilized with ice-cold methanol overnight at −20°C. The next day, cells were washed twice with CyFACS and incubated with a cocktail of 11 intracellular antibodies on ice for 1 h (Table S1 ). Cells were washed, suspended in CyPBS containing iridium-intercalator (DNA stain; Fluidigm) and 2% PFA, and stored at 4°C overnight. Before acquisition on a CyTOF2 mass cytometer (Fluidigm), cells were counted, washed with ddH 2 O water, and suspended in EQ Four Element calibration beads (Fluidigm) per the manufacturer's instructions. Normalization was performed using Normalizer v0.3 Matlab Complier Runtime (GitHub; Nolan laboratory), and Cytobank (cytobank.org) was used for data analysis and generation of SPA DE trees, viSNE maps, and heat maps. Splenocyte populations were clustered in each viSNE map by CD45, CD4, CD8α, CD11b, Ly6G, CD3ε, CD19, NK1.1, and MHC II, whereas thymocyte populations were clustered by 3291 JEM Vol. 214, No. 11 CD45, TCRβ, CD4, CD8α, CD11b, Ly6G, TER119, TCRγδ, B220, CD3ε, CD19, NK1.1, CD117, and MHC II. Natural separations in the viSNE map combined with marker-dependent color-coding of dot plots were used to manually draw gates and define populations. Cell populations represented in SPA DE trees and heat maps were also manually defined according to cell surface marker expression as explained in Table  S2 . For analysis of heat map data and comparison of signal intensity, log 10 scales were compressed according to the arcsinh transformation as previously described (Bendall et al., 2011) and in accordance with the standard analytical procedure for mass cytometry data on cytobank.org.
Staining of tissue
Tissue was isolated from STI NG N153S, WT littermate control, Irf3 −/− , and Irf3 −/− STI NG N153S mice, fixed in 4% PFA for 24 h at 4°C, and resuspended in 70% ethanol before being embedded in paraffin blocks. Tissue sections were subjected to hematoxylin and eosin or Gomori trichrome staining. Samples were imaged using a Nikon Eclipse E400 microscope and NIS Elements software. The percentage of lung comprised of perivascular inflammatory lesions in each mouse was determined by averaging the measurements of two random fields using ImageJ (Schneider et al., 2012) .
Flow cytometry
Immunophenotyping of spleens was performed on a FAC SCanto flow cytometer (BD Biosciences) and analyzed using FlowJo software.
Statistics
Unless otherwise specified, all data were analyzed using Graph-Pad Prism software by Mann-Whitney or t test as specified in the figure legends. Flow cytometry data were analyzed using FlowJo, and CyTOF results were analyzed using cytobank.org. online supplemental material Supplemental material associated with this study includes FACS characterization of infiltrating immune cells in the lungs of STI NG N153S mice (Fig. S1) , as well as a comparison of type I IFN and ISG induction in patient and mouse fibroblasts and also in transfected 293T cells (Fig.  S2 ). Supplemental tables include CyTOF panels (Table  S1 ) and definitions of immune cell populations from CyTOF analysis (Table S2 ).
